Moleculin Biotech announces notice of allowance for JPO covering Annamycin

Moleculin Biotech (MBRX) announced that the Japan Patent Office, JPO, has issued a notice of allowance for Patent Application No. 2021-577862 titled, “Method of reconstituting Liposomal Annamycin.” A patent from the application is expected to be issued in the coming months. “Securing strong patent protection across key global markets remains a core strategic priority as we advance our non-cardiotoxic therapy for relapsed or refractory acute myeloid leukemia through pivotal Phase 3 development,” commented Walter Klemp, Chairman and CEO of Moleculin. “This newly allowed Japanese patent further strengthens our international intellectual property position by protecting critical methods supporting the preparation and clinical use of our therapy, reinforcing our confidence in its long-term value as we work toward potential regulatory approval and commercialization in key territories worldwide.”